PUT - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 08:07:14 2024-07-01 EDT | ||
| 1.59 EUR | +6.00% |
|
| Current month | -85.69% | ||
| 1 month | -86.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 1.59 | +6.00% |
| 24-06-28 | 1.5 | -35.34% |
| 24-06-27 | 2.32 | -15.64% |
| 24-06-26 | 2.75 | +18.03% |
| 24-06-25 | 2.33 | -15.27% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 08:07 am
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0CJU |
| ISIN | DE000VD0CJU4 |
| Date issued | 2024-02-14 |
| Strike | 925.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 17.22 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.89 € |
|---|---|
| Lowest since issue | 1.15 € |
| Spread | 0.22 € |
| Spread % | 12.15% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- Certificat
